Advertisement

Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study)

  • Guang Zhong Liu
  • Song Zhang
  • Dang Hui Sun
  • Jing Shi
  • Wan Lan Bo
  • Wen Nan Wang
  • Chong Yang Zhang
  • Zhong Hua Wang
  • Wei Feng
  • Mei Jiao He
  • Yuan Yuan Liu
  • Shuang Li
  • Lin Qun Zheng
  • Yue LiEmail author
Clinical Trial
  • 37 Downloads

Abstract

Purpose

High on-treatment platelet reactivity (HTPR) after clopidogrel administration in patients with acute coronary syndrome (ACS) has been associated with an increased risk of adverse events. Our previous studies reported that half-dose ticagrelor provides a similar inhibitory effect on adenosine diphosphate (ADP)–induced platelet aggregation as standard-dose ticagrelor, but half-dose of ticagrelor has not been studied in Chinese ACS patients with HTPR. This study aimed to compare the antiplatelet action of half-dose ticagrelor with high-dose clopidogrel in ACS patients with HTPR.

Methods

In this single-center randomized controlled trial, 80 (of 418 screened, 19.13%) ACS patients with HTPR while on clopidogrel were randomized to either half-dose ticagrelor (90 mg LD, then 45 mg twice daily) or high-dose clopidogrel (150 mg once daily). Platelet function was assessed by thromboelastography (TEG) and light transmission aggregometry (LTA), and adverse events were monitored throughout the study for 30 days.

Results

The ADP-induced platelet inhibition rate (IR) as measured by TEG was significantly higher for half-dose ticagrelor compared with high-dose clopidogrel (70.40% [61.10%–91.70%] vs. 44.25% [34.67%–79.07%], p = 0.001). The repeated HTPR rate was dramatically higher for high-dose clopidogrel compared with half-dose ticagrelor (6 of 32, 18.75% vs. 1 of 35, 2.85%; p = 0.04). No patients in either treatment group exhibited a major bleeding event or other adverse events.

Conclusions

In ACS patients with HTPR, half-dose ticagrelor is more effective than high-dose clopidogrel in reducing platelet reactivity (NCT03062462).

Keywords

ACS Ticagrelor Clopidogrel HTPR 

Notes

Acknowledgements

We are grateful to Dr. Tian Kai Li, Dr. Hong Jie Xue, and Dr. Jing Yi Xue in the department of Cardiology, the First Affiliated Hospital, Harbin Medical University. The authors would like to acknowledge the department of Clinical Pharmacology of the First Affiliated Hospital, Harbin Medical University.

Contributor information

Guang Zhong Liu, Song Zhang, Dang Hui Sun, and Yue Li designed and conducted the experiment. Guang Zhang Liu, Song Zhang, and Dang Hui Sun analyzed the data and wrote the manuscript. Jing Shi, Wan Lan Bo, Wen Nan Wang, Chong Yang Zhang, Zhong Hua Wang, Wei Feng, Mei Jiao He, Yuan Yuan Liu, Shuang Li, and Lin Qun Zheng conducted the experiments. Guang Zhong Liu, Song Zhang, and Yue Li revised the manuscript. All authors approved the final version of the manuscript.

Funding

The study was funded by the National Nature Scientific Foundation of China (No. 81700305, No. 81300133, No. 81470462), the Fundamental Research Funds for the Provincial Universities of Heilongjiang (2017LCZX09), Heilongjiang Provincial Youth Innovative Talent Training Program(UNPYSCT-2017067), the Health Commission of Heilongjiang Province Research Project in China (Grant No. 2018072), and the Research Funds from the First Affiliated Hospital of Harbin Medical University (2017B006).

Compliance with ethical standards

The study was conducted in accordance with International Conference on Harmonization Guideline for Good Clinical Practice and Declaration of Helsinki and was approved in advance by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University. All subjects provided written informed consents before their participation.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. Jama 306(11):1215–1223.  https://doi.org/10.1001/jama.2011.1332 CrossRefGoogle Scholar
  2. 2.
    Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58(19):1945–1954.  https://doi.org/10.1016/j.jacc.2011.06.059 CrossRefGoogle Scholar
  3. 3.
    Mayer K, Sibbing D (2012) Platelet hyperreactivity and stent thrombosis in patients undergoing coronary stenting. Curr Vasc Pharmacol 10(5):597–605CrossRefGoogle Scholar
  4. 4.
    Mangiacapra F, Barbato E, Patti G, Gatto L, Vizzi V, Ricottini E, D'Ambrosio A, Wijns W, Di Sciascio G (2010) Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. JACC Cardiovasc Interv 3(3):318–323.  https://doi.org/10.1016/j.jcin.2009.12.012 CrossRefGoogle Scholar
  5. 5.
    Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F (2012) Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv 5(5):698–704.  https://doi.org/10.1161/circinterventions.112.972463 CrossRefGoogle Scholar
  6. 6.
    Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 56(2):134–143.  https://doi.org/10.1016/j.jacc.2009.12.071 CrossRefGoogle Scholar
  7. 7.
    Alexopoulos D, Perperis A, Koniari I, Karvounis H, Patsilinakos S, Ziakas A, Barampoutis N, Panagiotidis T, Akinosoglou K, Hahalis G, Xanthopoulou I (2015) Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis 40(3):261–267.  https://doi.org/10.1007/s11239-015-1183-9 CrossRefGoogle Scholar
  8. 8.
    Zhang Y, Zhao Y, Pang M, Wu Y, Zhuang K, Zhang H, Bhat A (2016) High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial. Acta Cardiol 71(3):309–316.  https://doi.org/10.2143/ac.71.3.3152091 CrossRefGoogle Scholar
  9. 9.
    Bavishi C, Panwar S, Messerli FH, Bangalore S (2015) Meta-analysis of comparison of the newer oral P2Y12 inhibitors (prasugrel or ticagrelor) to clopidogrel in patients with non-ST-elevation acute coronary syndrome. Am J Cardiol 116(5):809–817.  https://doi.org/10.1016/j.amjcard.2015.05.058 CrossRefGoogle Scholar
  10. 10.
    Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372(19):1791–1800.  https://doi.org/10.1056/NEJMoa1500857 CrossRefGoogle Scholar
  11. 11.
    Harding SA, Holley A, Wilkins B, Fairley S, Simmonds M, Larsen PD (2017) Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor? Intern Med J 47(11):1298–1305.  https://doi.org/10.1111/imj.13595 CrossRefGoogle Scholar
  12. 12.
    Lemesle G, Schurtz G, Bauters C, Hamon M (2015) High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost 13(6):931–942.  https://doi.org/10.1111/jth.12907 CrossRefGoogle Scholar
  13. 13.
    Xue HJ, Shi J, Liu B, Wang DY, Dong ZX, Guo H, Kong YH, Sheng L, Shao Q, Sun DH, Zhang L, Pan YJ, Dong XW, Li JQ, Xue JY, Zhou YY, Yang HP, Li Y (2016) Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS. Platelets 27(5):440–445.  https://doi.org/10.3109/09537104.2015.1135890 CrossRefGoogle Scholar
  14. 14.
    He M, Liu B, Sun D, Pan Y, Zheng W, Shi J, Zhao S, Dong X, Lu S, Li M, Han Y, Li Y (2016) One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: a randomized, single-blind, crossover clinical study. Int J Cardiol 215:209–213.  https://doi.org/10.1016/j.ijcard.2016.04.087 CrossRefGoogle Scholar
  15. 15.
    Zhang HZ, Kim MH, Jeong YH (2014) Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets 25(4):292–299.  https://doi.org/10.3109/09537104.2013.815341 CrossRefGoogle Scholar
  16. 16.
    Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 46(10):1820–1826.  https://doi.org/10.1016/j.jacc.2005.07.041 CrossRefGoogle Scholar
  17. 17.
    Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA (2007) Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate. J Am Coll Cardiol 49(6):657–666.  https://doi.org/10.1016/j.jacc.2006.10.050 CrossRefGoogle Scholar
  18. 18.
    Jeong YH (2014) “East Asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep 16(5):485.  https://doi.org/10.1007/s11886-014-0485-4 CrossRefGoogle Scholar
  19. 19.
    Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614–623.  https://doi.org/10.1016/s0140-6736(13)61170-8 CrossRefGoogle Scholar
  20. 20.
    Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261–2273.  https://doi.org/10.1016/j.jacc.2013.07.101 CrossRefGoogle Scholar
  21. 21.
    Jeong YH, Bliden KP, Antonino MJ, Tantry US, Gurbel PA (2013) Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. Platelets 24(2):166–169.  https://doi.org/10.3109/09537104.2012.675108 CrossRefGoogle Scholar
  22. 22.
    Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr (2014) Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol 11(10):597–606.  https://doi.org/10.1038/nrcardio.2014.104 CrossRefGoogle Scholar
  23. 23.
    Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY (2011) The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 127(1):23–28.  https://doi.org/10.1016/j.thromres.2010.10.021 CrossRefGoogle Scholar
  24. 24.
    Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet JP, Montalescot G, Cazenave JP, Dickele MC, Monassier JP, Gachet C (2008) Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 1(6):631–638.  https://doi.org/10.1016/j.jcin.2008.09.004 CrossRefGoogle Scholar
  25. 25.
    Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, Zenni MM, Guzman LA, Bass TA, Costa MA (2007) Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115(6):708–716.  https://doi.org/10.1161/circulationaha.106.667741 CrossRefGoogle Scholar
  26. 26.
    Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11):1097–1105.  https://doi.org/10.1001/jama.2011.290 CrossRefGoogle Scholar
  27. 27.
    Lin L, Wang H, Chen YF, Lin WW, Wang CL, Lin CH (2015) High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. Coron Artery Dis 26(5):386–395.  https://doi.org/10.1097/mca.0000000000000246 CrossRefGoogle Scholar
  28. 28.
    Ma W, Liang Y, Zhu J, Wang Y, Wang X (2015) Meta-analysis appraising high maintenance dose clopidogrel in patients who underwent percutaneous coronary intervention with and without high on-clopidogrel platelet reactivity. Am J Cardiol 115(5):592–601.  https://doi.org/10.1016/j.amjcard.2014.12.013 CrossRefGoogle Scholar
  29. 29.
    Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, Kim DK, Kim DK, Kim KH, Seol SH, Nam CW, Hur SH, Kim W, Park JS, Kim YJ, Kim DS (2013) High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. Int J Cardiol 167(5):1877–1881.  https://doi.org/10.1016/j.ijcard.2012.04.154 CrossRefGoogle Scholar
  30. 30.
    Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, Gao R, Yang Y (2018) Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual anti-platelet in patients with high post-treatment platelet reactivity: results of the CREATIVE trial (Clopidogrel Response Evaluation and AnTi-platelet InterVEntion in High Thrombotic Risk PCI Patients). Circulation.  https://doi.org/10.1161/circulationaha.117.030190
  31. 31.
    Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 4(4):403–410.  https://doi.org/10.1016/j.jcin.2010.12.011 CrossRefGoogle Scholar
  32. 32.
    Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J, Wang Z, Zhao X, Qin Y, Ma L (2015) Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep 5:13789.  https://doi.org/10.1038/srep13789 CrossRefGoogle Scholar
  33. 33.
    Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, Makris G, Damelou A, Tsigkas G, Hahalis G, Davlouros P (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60(3):193–199.  https://doi.org/10.1016/j.jacc.2012.03.050 CrossRefGoogle Scholar
  34. 34.
    Wu B, Lin H, Tobe RG, Zhang L, He B (2017) Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials. J Comp Eff Res.  https://doi.org/10.2217/cer-2017-0074
  35. 35.
    Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Theroux P, Hamm C, Spinar J, Kiss RG, Dalby AJ, Medina FA, Kontny F, Aylward PE, Jensen EC, Held P, Braunwald E, Sabatine MS (2016) Long-term tolerability of ticagrelor for the secondary prevention of major adverse cardiovascular events: a secondary analysis of the PEGASUS-TIMI 54 trial. JAMA Cardiol 1(4):425–432.  https://doi.org/10.1001/jamacardio.2016.1017 CrossRefGoogle Scholar
  36. 36.
    Bergmeijer TO, Janssen PWA, van Oevelen M, van Rooijen D, Godschalk TC, Kelder JC, Deneer VHM, Serebruany VL, Ten Berg JM (2017) Incidence and causes for early ticagrelor discontinuation: a “real-world” Dutch registry experience. Cardiology 138(3):164–168.  https://doi.org/10.1159/000475705 CrossRefGoogle Scholar
  37. 37.
    Guo LZ, Kim MH, Jin CD, Lee JY, Yi SJ, Park MK, Cho YR, Park TH (2015) Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets 26(6):563–569.  https://doi.org/10.3109/09537104.2014.959913 CrossRefGoogle Scholar
  38. 38.
    Hiasa Y, Teng R, Emanuelsson H (2014) Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther 29(4):324–333CrossRefGoogle Scholar
  39. 39.
    Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS (2017) Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol 70(11):1368–1375.  https://doi.org/10.1016/j.jacc.2017.07.768 CrossRefGoogle Scholar
  40. 40.
    Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723–731.  https://doi.org/10.1016/s0140-6736(09)60441-4 CrossRefGoogle Scholar
  41. 41.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057.  https://doi.org/10.1056/NEJMoa0904327 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Guang Zhong Liu
    • 1
  • Song Zhang
    • 1
  • Dang Hui Sun
    • 1
  • Jing Shi
    • 1
  • Wan Lan Bo
    • 1
  • Wen Nan Wang
    • 1
  • Chong Yang Zhang
    • 1
  • Zhong Hua Wang
    • 1
  • Wei Feng
    • 1
  • Mei Jiao He
    • 1
  • Yuan Yuan Liu
    • 1
  • Shuang Li
    • 1
  • Lin Qun Zheng
    • 1
  • Yue Li
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Cardiology, the First Affiliated HospitalHarbin Medical UniversityHarbinChina
  2. 2.Key Laboratory of Cardiac Diseases and Heart FailureHarbin Medical UniversityHarbinChina
  3. 3.Institute of Metabolic DiseaseHeilongjiang Academy of Medical ScienceHarbinChina

Personalised recommendations